Product Description
Memantine is used to treat the symptoms of Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Memantine is in a class of medications called NMDA receptor antagonists. It works by decreasing abnormal activity in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a604006.html)
Mechanisms of Action: NMDA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Alzheimer Disease | Dementia
Known Adverse Events: Dizziness | Headache | Ecchymosis | Anorexia | Diarrhea
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Russia, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Brain Cancer|Dementia, Vascular
Phase 2: Alzheimer Disease|Cognitive Dysfunction|Lupus Erythematosus, Systemic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CCTG CE.7 | P3 |
Recruiting |
Brain Cancer |
2027-06-30 |
|
| ClearMEMory | P2 |
Recruiting |
Lupus Erythematosus, Systemic|Cognitive Dysfunction |
2026-06-01 |
|
| ACTRN12624001274561 | P1 |
Not yet recruiting |
Alzheimer Disease |
2025-01-31 |
|
| MIND | P3 |
Completed |
Dementia, Vascular |
2022-06-01 |
38% |